Search
Xelaglifam
go.drugbank.com/drugs/DB21598InvestigationalXelaglifam is under investigation in clinical trial NCT04982705 (IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics). Xelaglifam has a monoisotopic molecular weight of 501.2 Da.
Managlinat dialanetil
go.drugbank.com/drugs/DB05518InvestigationalCS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
Idronoxil
go.drugbank.com/drugs/DB04915InvestigationalIdronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.
TD-2749
go.drugbank.com/drugs/DB05905ExperimentalTD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders
Ulixertinib
go.drugbank.com/drugs/DB13930InvestigationalIt is currently in clinical trials for the treatment of a wide range of tumors.
Ultevursen
go.drugbank.com/drugs/DB17835InvestigationalIt was developed by ProQR Therapeutics and is being investigated for the treatment of retinitis pigmentosa.
Radotermin
go.drugbank.com/drugs/DB19127InvestigationalRadotermin is under investigation in clinical trial NCT01182337 (A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal Rhgdf-5 for the
COCAINE ESTERASE (RBP-8000)
go.drugbank.com/drugs/DB19225InvestigationalRBP-8000 is under investigation in clinical trials (A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse) for the treatment of Cocaine
Clofutriben
go.drugbank.com/drugs/DB21636InvestigationalClofutriben is under investigation in clinical trial NCT05307328 (SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome).
Siagoside
go.drugbank.com/drugs/DB12351InvestigationalSiagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. … Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to be beneficial in patients with severe spinal cord injury.